Item 1. Security and Issuer
This Amendment No. 2 to Schedule 13D (this “Amendment No. 2”) relates to the Common Stock of Orbotech Ltd., (the “Issuer” or the “Company”) and amends the Schedule 13D filed on April 2, 2014 (the “Original Schedule 13D”), as amended by Amendment No. 1 thereto filed on May 20, 2014 (the Original Schedule 13D, and as amended by Amendment No. 1 and this Amendment No. 2, the “Schedule 13D”). The address of the Issuer’s principal executive offices is Orbotech Park Ltd., P.O. Box 215, Yavne, Israel 81102. This Amendment No. 2 is being filed by Ion Asset Management Ltd. (the “Management Company”), Jonathan Half, and Steven Levey (collectively, the “Reporting Persons”).
This Amendment No. 2 is being filed to amend Item 4, Item 5 and Item 7 of the Schedule 13D as follows:
Item 4. Purpose of Transaction
Item 4 of the Schedule 13D is amended by adding thereto the following:
On June 9, 2014, the Management Company sent a letter to the Board of Directors of the Issuer, expressing concerns about the Issuer’s persistent underperformance and long term shareprice performance, which the Management Company believes is a result of a weak and entrenched Board of Directors. The Management Company requested that the Board revise the proxy statement issued on June 5, 2014 to add the following three items to the agenda for the 2014 Annual General Meeting (“AGM”): 1) nomination of four highly qualified and experienced board member nominees to stand against the three incumbent Directors and one proposed new external Director; 2) a proposal to remove the staggered board structure and move to a declassified structure; and 3) a proposal that the Board review every Q2 and Q4 the capital structure of the Issuer, dividend, and share repurchase policy. A committee of the Board comprised of those directors of the Issuer who qualify as independent would make a recommendation to the Board prior to such review and upon request of the committee, the Issuer will publish the results of the Board’s review.
The Management Company further requested that the Board consider delaying the AGM, currently scheduled for July 10, 2014, to allow investors to review the new proposals and vote accordingly, and urged investors to delay voting until the new proxy document has been received. A copy of the letter, with its appendices, is filed herewith as Exhibit 99.2 and incorporated herein by reference. The description of the letter contained in this Amendment No. 2 is qualified in its entirety by reference to Ex. 99.2 hereto.
Item 5. Interest in Securities of the Issuer
Item 5 of the Schedule 13D is amended to reflect the following:
On June 5, 2014, the Issuer filed a Form 6-K in which the Issuer reported 41,629,567 shares of Common Stock outstanding as of June 2, 2014, representing a decrease in the number of shares of Common Stock outstanding as previously reported by the Issuer. Solely as a result of such decrease, the shares of Common Stock beneficially owned by the Reporting Persons represent approximately 6.17% of the Common Stock outstanding, as reflected on pages 2-4 of this Amendment No. 2.
Item 7. Material to be filed as Exhibits
Item 7 of the Schedule 13D is amended by adding thereto the following:
Exhibit 99.2 – The Management Company’s Letter to the Board of Directors of the Issuer, and Appendices (dated June 9, 2014).